1 Ye W, Liu CW, Ricco JB, Mani K, Zeng R, Jiang J. Early and late outcomes of percutaneous treatment of TransAtlantic Inter-Society Consensus class C and D aorto-iliac lesions. Journal of vascular surgery. Jun 2011; 53(6):1728-1737.
2 Jongkind V, Akkersdijk GJ, Yeung KK, Wisselink W. A systematic review of endovascular treatment of extensive aortoiliac occlusive disease. Journal of vascular surgery. Nov 2010;52(5):1376–83.
3 Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. Jul 1997;204(1):87–96.
4 Capoccia L, Riambau V, da Rocha M. Is femorofemoral crossover bypass an option in claudication? Annals of vascular surgery. Aug 2010;24(6):828–32.
5 Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al; 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases. The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018 Mar 1;39(9):763–816.
6 de Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. Journal of vascular surgery. Oct 1997;26(4):558–69.
7 Goueffic Y, Della Schiava N, Thaveau F, Rosset E, Favre JP, et al. Stenting or Surgery for De Novo Common Femoral Artery Stenosis. JACC Cardiovasc Interv. 2017 10;10:1344–54.
8 Deloose K, Marins I, Neves C, Callaert J. Endovascular treatment of the common femoral artery: is there a challenge to open surgery? J Cardiovasc Surg. 2019;60(1):8–13.
9 Laird JA, Schneider PA, Jaff MR, Brodmann M, Zeller T, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. Circ Cardiovasc Interv. 2019 Jun;12(6):e007702.
10 Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013 18;61:2417–27.
11 Nolan B, Finlayson S, Tosteson A, Powell R, Cronenwett J. The treatment of disabling intermittent claudication in patients with superficial femoral artery occlusive disease--decision analysis. Journal of vascular surgery. Jun 2007;45(6):1179–84.
12 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2018 Dec 18;7(24).
13 Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, et al. Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon. J Am Coll Cardiol. 2019 May 28;73(20):2550–63.
14 Zeller T, Beschorner U, Pilger E, Bosiers M, Deloose K, et al. Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial. JACC Cardiovasc Interv. 2015;8(12):1614–22.
15 Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014 14;64(15):1568–76.
16 Rastan A, Brechtel K, Krankenberg H, Zahorsky R, Tepe G, et al, – wenn auch die vorliegende Evidenz weiterhin kontrovers diskutiert wird. , Neumann FJ, Zeller T. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol. 2012 Aug 14;60(7):587–91.
17 Scheinert D, Katsanos K, Zeller T, Koppensteiner R, Commeau P, et al; A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012 Dec 4;60(22):2290–5.
18 Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European heart journal. 2007;28:2375–414.
19 Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European heart journal. 2016;37:2315–81.
20 Bullen C. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease. Expert Review of Cardiovascular Therapy. 2008;6:883–95.
21 Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380:2224–60.
22 Staessen JA, Thijs L, Gąsowski J, Cells H and Fagard RH. Treatment of isolated systolic hypertension in the elderly: further evidence from the Systolic Hypertension in Europe (Syst-Eur) trial. The American Journal of Cardiology. 1998;82:20–2.
23 Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2013;31:1281–357.
24 Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine. 2015;373:2103–16.
25 Cushman WC, Whelton PK, Fine LJ, et al. SPRINT Trial Results. Hypertension. 2016;67:263–5.
26 Bavry AA, Anderson RD, Gong Y, et al. Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease. Hypertension. 2010;55:48–53.
27 Aronow WS and Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. The American Journal of Cardiology. 2001;87:1284–6.
28 Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European heart journal. 2020 Jan 7;41(2):255–323.
29 Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European heart journal. 2017;38:2459–72.
30 Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European heart journal. 2020 Jan 1;41(1):111–188.
31.